May 2024
FDA Panel to Evaluate Lykos’ Innovative Psychedelic Treatment for Post-Traumatic Stress Disorder
FDA, Lykos, psychedelic therapy, PTSD, mental health, clinical trials, review panel, innovative treatment, mental health breakthrough.
Zenas Biotech Secures $200 Million for Advancing Obexelimab in Pivotal Immunology Trials
Zenas Biotech, obexelimab, immunology trials, funding, biotechnology, drug development, autoimmune diseases, B-cell-directed therapy.
FDA to Review Lilly’s Alzheimer’s Drug Donanemab in June Advisory Committee Meeting
FDA, Lilly, Alzheimer’s, donanemab, June, AdCom, review, approval, treatment, neurodegenerative disease.
Intellectual property landscape around prime editing
Intellectual Property Landscape Around Prime Editing Prime editing, a revolutionary genome editing technology, has been at the forefront of significant intellectual property developments and patent disputes. This technology, which allows for precise DNA edits without the need for double-strand breaks, was developed by Dr. David Liu and his team at the Broad Institute and Harvard […]
What is the difference between prime editing and CRISPR/Cas9
The difference between Prime Editing and CRISPR/Cas9 lies in their mechanisms of editing DNA, their efficiency, precision, and the types of genetic modifications they can achieve. Mechanism of Editing Efficiency and Precision Types of Genetic Modifications In summary, while both Prime Editing and CRISPR/Cas9 are groundbreaking genome editing tools, Prime Editing offers a more precise […]
ADC Therapeutics Showcases Promising Zynlonta Data in Marginal Zone Lymphoma and Secures $105M in Funding
ADC Therapeutics, Zynlonta, marginal zone lymphoma, share sale, funding, cancer treatment, antibody-drug conjugate, clinical trials, biotechnology, healthcare.
AstraZeneca Strengthens Partnership with Cellectis in Cell and Gene Therapy Advancement
AstraZeneca, Cellectis, cell therapy, gene therapy, partnership, stake, discovery, pact, biotechnology, healthcare, investment, innovation, medical research, therapeutic development.
GlycoMimetics’ Uproleselan Fails to Meet Primary Endpoint in Leukemia Clinical Trial
GlycoMimetics, Uproleselan, Leukemia, Clinical Trial, Primary Endpoint, Stock Market Reaction
Pfizer Appoints Citi Analyst Andrew Baum as New Strategy Chief
Pfizer, Andrew Baum, Citi analyst, strategy chief, pharmaceutical industry, leadership change, strategic planning.
Chiesi Invests Heavily in Gossamer’s Promising Pulmonary Hypertension Treatment
Chiesi, Gossamer, pulmonary hypertension, drug development, investment, collaboration, GD-001, clinical trials, cardiovascular diseases.